Evidence map›Paper›PMID 26138469›Full record

ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2015

Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.

Aditya J Desai, Maoqing Dong, Kaleeckal G Harikumar, Laurence J Miller

Abstract read
In one paragraph

Article in American journal of physiology. Gastrointestinal and liver physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aditya J DesaiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona.
Maoqing DongDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona.
Kaleeckal G HarikumarDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona.
Laurence J MillerDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona miller@mayo.edu.

Funding

Type A CCK Receptor Structure, Function and RegulationR37DK032878 · NIDDK · MAYO CLINIC COLL OF MED, MAYO CLINIC AZ · PI MILLER, LAURENCE J · 2001 to 2010
$4.5M
Type A CCK Receptor Structure, Function & RegulationR01DK032878 · NIDDK · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI MILLER, LAURENCE J · 1986 to 2014
$2.5M
NIDDK NIH HHS DK-032878
6 · The paper itself

Abstract

Dysfunction of the type 1 cholecystokinin (CCK) receptor (CCK1R) as a result of increased gallbladder muscularis membrane cholesterol has been implicated in the pathogenesis of cholesterol gallstones. Administration of ursodeoxycholic acid, which is structurally related to cholesterol, has been shown to have beneficial effects on gallstone formation. Our aims were to explore the possible direct effects and mechanism of action of bile acids on CCK receptor function. We studied the effects of structurally related hydrophobic chenodeoxycholic acid and hydrophilic ursodeoxycholic acid in vitro on CCK receptor function in the setting of normal and elevated membrane cholesterol. We also examined their effects on a cholesterol-insensitive CCK1R mutant (Y140A) disrupting a key site of cholesterol action. The results show that, similar to the impact of cholesterol on CCK receptors, bile acid effects were limited to CCK1R, with no effects on CCK2R. Chenodeoxycholic acid had a negative impact on CCK1R function, while ursodeoxycholic acid had no effect on CCK1R function in normal membranes but was protective against the negative impact of elevated cholesterol on this receptor. The cholesterol-insensitive CCK1R mutant Y140A was resistant to effects of both bile acids. These data suggest that bile acids compete with the action of cholesterol on CCK1R, probably by interacting at the same site, although the conformational impact of each bile acid appears to be different, with ursodeoxycholic acid capable of correcting the abnormal conformation of CCK1R in a high-cholesterol environment. This mechanism may contribute to the beneficial effect of ursodeoxycholic acid in reducing cholesterol gallstone formation.

Indexed as

AnimalsBinding SitesChenodeoxycholic AcidCHO CellsCholesterolCricetinaeCricetulusDigestionMutationProtein BindingReceptor, Cholecystokinin AUrsodeoxycholic AcidChenodeoxycholic AcidCholesterolReceptor, Cholecystokinin AUrsodeoxycholic Acidbile acidscholecystokinincholesterolgallstone disease

Identifiers

PMID26138469
PMCPMC4556949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.